Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Tower Corp (AMT) vs Gilead Sciences, Inc. (GILD) Price & Performance

American Tower CorpTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

American Tower Corp vs Gilead Sciences, Inc. — how do they compare? American Tower Corp trades at $169.8 (market cap $79.00B), while Gilead Sciences, Inc. trades at $136.31 (market cap $168.35B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× American Tower Corp's market cap, and American Tower Corp pays the higher dividend (4.12%). Which is the better fit depends on your goals.

AMTGILD
Market Cap
$79.00B$168.35B
Sector
Real EstateHealth
52-Week High
$211.88$155.80
52-Week Low
$162.11$110.56
Enterprise Value
$122.53B$191.42B
Dividend Yield
4.12%2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Tower Corp

American Tower Corporation (AMT) trades at $170.48, up 0.81% with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals despite analyst optimism, with 79.6% buy ratings and a $206.17 consensus price target representing 21% upside potential. Recent Q2 2026 results demonstrated accelerated lease contract growth and raised full-year guidance.

AMT presents a compelling investment case with strong revenue visibility from telecom infrastructure demand and 5G/6G expansion cycles. However, high debt levels and interest rate sensitivity pose significant risks. The stock offers defensive characteristics through recurring revenue streams but faces headwinds from DISH Network churn and capital expenditure requirements.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.

The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Tower Corp

American Tower owns and operates more than 220,000 cell towers throughout the U.S., Asia, Latin America, Europe, and Africa. It also owns and/or operates 25 data centers in eight U.S. markets after acquiring CoreSite. On its towers, the company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. The company operates more than 40,000 towers in the U.S., which accounted for more than half of its total revenue in 2021. Outside the U.S., American Tower's greatest presence is in India and Brazil, where it operates roughly 75,000 and 19,000 towers, respectively. American Tower operates as a real estate investment trust.

Read more on AMT

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD